The Joint Corp.

NASDAQ•JYNT

CEO: Mr. Jake Singleton CPA

セクター: Healthcare

業種: Medical - Care Facilities

上場日: 2014-11-11

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

連絡先情報

16767 North Perimeter Drive, Suite 110, Scottsdale, AZ, 85260, United States

480-245-5960

www.thejoint.com

時価総額

$136.57M

PER (TTM)

41.9

30.4

配当利回り

52週高値

$13.00

52週安値

$7.50

52週レンジ

38%

順位38Top 36.9%

4.3

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

堅調 • 4.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$14.82M+0.00%

直近4四半期の推移

EPS

$0.09+0.00%

直近4四半期の推移

フリーCF

-$1.71M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Continuing Revenue Growth Total revenues increased 5.2% to $54.90B, driven by expansion in franchised clinics operating during 2025.

Franchise Fee Strength Franchise fees grew 12.5% to $3.37B, reflecting successful license sales and accelerated recognition from terminations.

Continuing Operations Loss Narrows Loss from continuing operations significantly improved by 51.6%, reducing the loss to $(913.4M) compared to 2024.

Adjusted EBITDA Rises Total Adjusted EBITDA increased to $12.97B, up from $11.38B in the prior year, showing operational leverage.

リスク要因

Labor Shortage Impacts Operations Nationwide labor shortage limited ability to open new clinics and required wage enhancements, reducing net revenues.

Economic Volatility Persists Fiscal 2026 expected to be volatile; elevated inflation and interest rates may reduce consumer discretionary spending.

Debt Covenant Violation Risk Default occurred on fixed charge coverage ratio covenant due to stock repurchases, prohibiting Revolver access until resolved.

Franchisee Performance Exposure Substantial revenue depends on franchisee success; declines in their revenue could harm royalty collections and brand goodwill.

見通し

Accelerate Pure-Play Transition Future growth focuses on accelerating franchise base development through strategic divestitures of all company-owned clinics.

Capital Allocation Goals Set Goal is to generate significant proceeds from sales for reinvestment, regional developer rights repurchase, or stock buybacks.

Margin Enhancement Strategy Expect to control corporate G&A expenses to grow slower than clinic base and sales, enhancing overall operating margins.

Clinic Development Pipeline Support franchisees to open 82 licensed clinics and pursue 57 letters of intent for future license development.

同業比較

売上高 (TTM)

DCGO

$301.71M

-42.0%

BTMD

$188.16M

-5.6%

CCLD

$124.14M

+10.3%

粗利益率 (最新四半期)

AGEN

98.3%

+83.9pp

JYNT

79.0%

-10.5pp

BTMD

67.1%

+1.3pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CLYM	$780.03M	-14.8	-31.5%	0.3%
IKT	$220.49M	-3.2	-41.3%	0.0%
APYX	$196.39M	-21.6	-90.6%	62.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

3.8%

緩やかな成長

4四半期純利益CAGR

140.5%

収益性の大幅な改善

キャッシュフロー安定性

75%

キャッシュフローの変動が大きい

深度リサーチ

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし